# REGENXBIO Inc. (RGNX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/RGNX
## Company Profile
- Ticker: RGNX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Gene Therapy, Rare Disease Gene Therapy, Rare Disease
## Stock Data
- Close: 9.2 USD
- Market cap: 337068488.91999996 USD
- Last updated: 2026-09-03
## Business Overview
REGENXBIO is a gene-therapy company focused on adeno-associated virus platform programs and rare diseases. Its story is built around platform delivery and the commercialization of gene-based medicines.
## Why The Stock Is Moving

As of Sep 3, 2026, RGNX closed down 4.17% at $9.20. No new same-company headline was identified in the current news window.

## Geographic Base

Headquartered in the United States and listed on NASDAQ, REGENXBIO sits in gene therapy.

## Business Model

The company depends on clinical validation, manufacturing execution, and the ability to create durable gene-therapy value.

## Landscape Position

REGENXBIO is a high-catalyst gene-therapy name whose valuation is tied to platform and clinical progress.

## Future Catalysts

- REGENXBIO's catalysts are its ocular gene-therapy programs and the broader rare-disease pipeline, with the market wanting proof the platform still has staying power. The next update matters if it shows the gene-therapy franchise can keep advancing.

## Recent News
- 2018-03-07 21:05 EST — [REGENXBIO to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/RGNX/regenxbio-to-participate-in-upcoming-investor-conferences-94fffe33) — Source: REGENXBIO Inc.
- 2018-03-06 21:01 EST — [REGENXBIO Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Operational Highlights](https://biopharmsignal.com/news/RGNX/regenxbio-reports-fourth-quarter-and-full-year-2017-financial-results-and-recent-5f9168e9) — Source: REGENXBIO Inc.
- 2018-02-27 21:05 EST — [REGENXBIO to Host Conference Call on March 6 to Discuss Fourth Quarter and Full-Year 2017 Financial Results and Recent Operational Highlights](https://biopharmsignal.com/news/RGNX/regenxbio-to-host-conference-call-on-march-6-to-discuss-fourth-quarter-and-full--aae23f43) — Source: REGENXBIO Inc.
- 2018-02-08 21:05 EST — [REGENXBIO Announces Completion of Dosing of Third Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD](https://biopharmsignal.com/news/RGNX/regenxbio-announces-completion-of-dosing-of-third-cohort-in-phase-i-clinical-tri-ae7e33fc) — Source: REGENXBIO Inc.
- 2018-01-23 21:10 EST — [REGENXBIO Enhances Gene Therapy Manufacturing Capabilities by Entering into Strategic Partnership with FUJIFILM Diosynth Biotechnologies](https://biopharmsignal.com/news/RGNX/regenxbio-enhances-gene-therapy-manufacturing-capabilities-by-entering-into-stra-a14b51df) — Source: REGENXBIO Inc.